Suchergebnisse - "Qin, Shukui"

PubPharm (310)

1

A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice

enthalten in: The oncologist | 2024

von Li, J. | Wang, Z. | Zhong, H. | +23

2

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma : final analysis of the randomized phase 2 FIGHT trial

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2024

von Wainberg, Z. | Kang, Y. | Lee, K. | +15

3

Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma-Reply

enthalten in: JAMA oncology | 2024

von Qin, S.

4

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : final results of a randomised phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Yau, T. | Kaseb, A. | Cheng, A. | +19

5

Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification : Preclinical and Clinical Evidence

enthalten in: JCO precision oncology | 2024

von Qin, S. | Pan, H. | Blanc, J. | +9

6

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

enthalten in: Gastric cancer | 2024

von Wainberg, Z. | Kang, Y. | Lee, K. | +15

7

Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers : a large-scale pooled analysis of 10 studies in China

enthalten in: Therapeutic advances in medical oncology | 2024

von Qu, W. | Wang, F. | Qin, S. | +2

8

Plain language summary of the HIMALAYA study : tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

enthalten in: Future oncology (London, England) | 2023

von Abou-Alfa, G. | Lau, G. | Kudo, M. | +27

9

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) : a randomised, double-blind, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Llovet, J. | Kudo, M. | Merle, P. | +123

ErratumIn: Lancet Oncol. 2024 Apr;25(4):e137. - PMID 38547896

10

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma : A Phase 3 Randomized Clinical Trial

enthalten in: JAMA oncology | 2023

von Qin, S. | Kudo, M. | Meyer, T. | +13

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[31]